Immuno-Oncology | Specialty

Ongoing Immuno-Oncology Research in Bladder Cancer

March 9th 2018

A Therapeutic Revolution: Immunotherapy for Bladder Cancer

March 9th 2018

Dr. Andre on Questions With Immunotherapy in Triple-Negative Breast Cancer

March 9th 2018

Fabrice André, MD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the remaining questions with immunotherapy agents as potential therapy for patients with triple-negative breast cancer. Andre expanded on this in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

Figlin Discusses Optimizing Expanding Treatment Options in RCC

March 8th 2018

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab

March 6th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care

FDA Approves 4-Week Nivolumab Dosing Schedule

March 6th 2018

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Optimal Sequencing Key to Capitalizing on RCC Advances

March 6th 2018

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

March 5th 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

Research Strategies to Improve Outcomes in GBM

March 5th 2018

GBM Emerging Strategies in Immunotherapy

March 5th 2018

GBM Rationale for Combining PD1 Inhibitor DNA Vaccine

March 5th 2018

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC

March 2nd 2018

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

DDR Alterations Associated With Increased Anti-PD-1/PD-L1 Activity in Bladder Cancer

March 2nd 2018

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

Optimizing Immunotherapy in Lung Cancer

March 1st 2018

Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.

Limitations in the Management of NETs

March 1st 2018

Developments in the NETs Treatment Landscape

March 1st 2018